0000000001104700

AUTHOR

Craxi A

showing 4 related works from this author

Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b

2021

HCV is an important cause of hepatocellular carcinoma (HCC). HCV NS5A domain-1 interacts with cellular proteins inducing pro-oncogenic pathways. Thus, we explore genetic variations in NS5A domain-1 and their association with HCC, by analyzing 188 NS5A sequences from HCV genotype-1b infected DAA-naïve cirrhotic patients: 34 with HCC and 154 without HCC. Specific NS5A mutations significantly correlate with HCC: S3T (8.8% vs. 1.3%, p = 0.01), T122M (8.8% vs. 0.0%, p &lt

hepatitis C virusLiver CirrhosisMaleCirrhosisvirusesHepacivirusViral Nonstructural ProteinsNS5Amedicine.disease_causeSeverity of Illness Indexgenetic variabilityMedicineLiver Neoplasmsvirus diseaseshepatocellular carcinomaMiddle AgedHepatitis CQR1-502Infectious DiseasesHepatocellular carcinomaHCVHost-Pathogen InteractionsFemaleDisease SusceptibilityCarcinoma HepatocellularGenotypeHepatitis C virusViremiaMicrobiologyArticleStructure-Activity RelationshipVirologyGenetic variationHumansGenetic variabilityNS5AneoplasmsAgedbusiness.industrycirrhosisSequence Analysis DNAbiochemical phenomena metabolism and nutritiongenotype 1bmedicine.diseaseSettore MED/17digestive system diseasesMutationCancer researchbusinessCarcinogenesisBiomarkersViruses
researchProduct

Oral dysphagia. An unique symptom for a wide spectrum of diseases

2009

Dysphagia, defined as a difficulty in swallowing of fluids and/or solid foods, is one of the most frequent symptoms of esophageal, gastrointestinal, ear, nose and throat diseases. As such, it poses a diagnostic challenge and an interdisciplinary clinical problem. Of particular importance in diagnosis is to distinguish between esophageal and oropharyngeal dysphagia. Oropharyn-geal dysphagia is often associated with neuromuscular disorders and is treated with rehabilitative protocols, while esophageal dysphagia may be due to anatomical alterations and esophageal motility difficulties. While the former can be adequately treated with endoscopic or surgical therapy, the latter are currently trea…

Diagnosis Differentialdysphagia oral cavity systemic diseasesSettore MED/28 - Malattie OdontostomatologichePredictive Value of TestsRisk FactorsPractice Guidelines as TopicHumansDeglutition DisordersDeglutition
researchProduct

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia

2012

Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are undergoing an elective invasive procedure.We randomly assigned 292 patients with chronic liver disease of diverse causes and platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14 days before a planned elective invasive procedure that was performed within 5 days after the last dose. The primary end point was the avoidance of a platelet transfusion before, during, and up to 7…

Liver CirrhosisMaleCirrhosisChronic liver diseaseBenzoateslaw.inventionchemistry.chemical_compoundRandomized controlled triallawReceptorsClinical endpoint80 and overMedicineCIRRHOSISAged 80 and overBenzoic AcidsGeneral MedicineCHRONIC LIVER DISEASEMiddle AgedHydrazinesThrombopoietinElective Surgical ProceduresAnesthesiaFemaleElective Surgical ProcedureReceptors ThrombopoietinAdultAdolescentEltrombopagELTROMBOPAGHemorrhagePlatelet TransfusionPlaceboYoung AdultDouble-Blind MethodElectiveSurgical Procedures ElectiveHumansAgedTHROMBOCYTOPENIA; ELTROMBOPAG; CIRRHOSIS; CHRONIC LIVER DISEASESurgical Proceduresbusiness.industryPlatelet CountTHROMBOCYTOPENIAcirrhosisSettore MED/09 - MEDICINA INTERNAmedicine.diseaseThrombocytopeniaPlatelet transfusionchemistryChronic DiseasePyrazolesbusiness
researchProduct

Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve …

2012

. In chronic hepatitis C (CHC), treatment duration may be individualized according to time to first undetectable hepatitis C virus (HCV) RNA, with patients who attain undetectable HCV RNA early in treatment being candidates for shorter regimens. The aim of this study was to determine the relapse rate in patients with CHC genotype (G) 1 infection and low baseline viral load who achieved undetectable HCV RNA by week 4 [rapid virologic response (RVR)] when treated for 24 weeks. This was an open-label, multicentre, noninterventional study. Adult patients with G1 CHC infection and baseline viral load <600,000 IU/mL who attained RVR were treated with peginterferon alfa-2b (1.5 mu g/kg/week) plus …

AdultMaleTime FactorsAdolescentGenotyperibavirinHepacivirusInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultRecurrenceRibavirinHumanspeginterferonhepatitis C virus genotyperelapseInterferon-alphaHepatitis C ChronicMiddle AgedViral LoadRecombinant Proteinsviral loadTreatment OutcomeHCVFemale
researchProduct